ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / NGEN / dividends
CUE (33) DERM (31) ALXO (50) MGNX (31) ⌘ Pro Terminal →

NervGen Pharma Corp. (NGEN) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.37 -4.86% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.36

NervGen Pharma Corp. (NGEN) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $155.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NGEN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, NervGen Pharma Corp. (NASDAQ: NGEN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $1.37 (-4.86% 1D, market cap $155.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, NGEN ranks #313 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NGEN compare to CUE and DERM in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NGEN carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CUE (Cue Biopharma Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $155.8M) and DERM (Journey Medical Corporation) posts a E grade (31/100 RQD, P/E N/A, ROIC -19.5%, cap $152.7M). Among the 5-stock peer group, NGEN leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NGEN?
▼

For NervGen Pharma Corp. (NGEN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #313 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.36 (-1.06%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510049
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (5)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4.4% Base Target
$7 Bull$1 Base$1 Bear
📬 FREE NGEN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NGEN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY NGEN SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($4.3M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
57
Grade C$1.73-11% Next Q
Q2 (-2Q)
54
Grade C-$1.54-7.8% Next Q
Q3 (-1Q)
52
Grade C-$1.42-3.5% Next Q
Current
49
Grade D$1.37-5.4% Hist 90D α
Trajectory: C (57) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NGEN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NGEN currently carries a cautious 49/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.88) and Max Pain ($1.44) forces dealer call-delta covering toward $6.62.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NGEN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NGEN Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 49%NO 51%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NGEN)

  • ✓Walkthrough of NGEN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NGEN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -62.57%🛡️ HOLDING TREND SUPPORT
2026-11-02O $1.45H $1.51L $1.37C $1.37VOL 123.1K
RES: $2.45SUP: $1.34SMA50: $1.88SMA200: $2.82
$4.19$3.42$2.65$1.88$1.11RES $2.45SUP $1.34$1.372026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NGEN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NGEN Butterfly Map → + Track NGEN →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NGEN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NGEN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NGEN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NGEN)

Health Care Rank #313 of 1016 ⚔️ CUE vs NGEN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NGEN vs. CUE, DERM, ALXO, MGNX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, NervGen Pharma Corp. (NGEN) ranks #313 by composite RQD confidence (49/100, grade D) and #605 by equity capitalization ($155.0M). Within this direct 5-issuer industry benchmark cohort, NGEN leads on earnings valuation at N/A trailing P/E, while DERM leads on capital efficiency and profitability with -19.5% ROIC and 65.8% gross margin. ALXO currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with NGEN at 49/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NGEN ACTIVE
NervGen Pharma Corp.
D 49/100 — — — -4.86% $155.0M Benchmark Subject
CUE
Cue Biopharma Inc.
E 33/100 — — -35.0% -2.70% $155.8M /cue-vs-ngen →
DERM
Journey Medical Corporation
E 31/100 — 65.8% -19.5% -4.44% $152.7M /derm-vs-ngen →
ALXO
ALX Oncology Holdings Inc.
D 50/100 — — -35.0% 0.00% $152.4M /alxo-vs-ngen →
MGNX
MacroGenics Inc.
E 31/100 — 96.0% -35.0% +0.84% $151.6M /mgnx-vs-ngen →

2. NGEN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

NervGen Pharma Corp. (NGEN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $155.0M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. NGEN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, NervGen Pharma Corp. (NASDAQ: NGEN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $1.37 (-4.86% 1D, market cap $155.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, NGEN ranks #313 in composite RQD confidence.

How does NGEN compare to CUE and DERM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NGEN carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CUE (Cue Biopharma Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $155.8M) and DERM (Journey Medical Corporation) posts a E grade (31/100 RQD, P/E N/A, ROIC -19.5%, cap $152.7M). Among the 5-stock peer group, NGEN leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NGEN?

For NervGen Pharma Corp. (NGEN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #313 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NGEN trading relative to its 50-day, 200-day, and 52-week technical levels?

NGEN last traded at $1.37 (-4.86% on volume of 546,945 shares), positioning the stock -27.13% below its 50-day simple moving average ($1.88) and -51.42% below its 200-day simple moving average ($2.82). Across its 52-week range of $1.35 to $6.30, NGEN sits at the 0.4% percentile with a 14-day RSI of 34.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.20 to $1.54).

NGEN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does NGEN pay a dividend and is it safe?

NervGen Pharma Corp. (NGEN) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: NGEN RQD Cockpit NGEN 12M Forecast NGEN Earnings & Move NGEN Dividends & DRIP NGEN Insiders & 13F NGEN Whale Options NGEN Profit Sankey NGEN News & Why
ROARABLE RATING BRIEF • RQD 49/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

NGEN — NervGen Pharma Corp.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:17:50Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, NGEN scores 49 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

  • Fundamental Cash Engine: 12 / 20. Per the Roarable RQD rating, ROIC is 0% and FCF yield is 0%. For a prospective investor, this means the pillar gives no evidence of current cash generation to support the price.
  • Whale (13F) Flow: 5 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. It is the lowest-scoring pillar, suggesting weak institutional support.
  • Insider Conviction: 9 / 20. Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. The below-midpoint score indicates limited insider conviction signals.
  • Macro Regime Fit: 10 / 20. Per the Roarable RQD rating, beta is 1.0 and the pillar reflects sector sensitivity. This is a neutral-to-weak read on how the stock may respond to market regime shifts.
  • Forensic Balance Sheet: 13 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. This is the strongest pillar, though it still sits below the midpoint.

Taken together, the rating frames NGEN as a stock where the balance sheet is the relative bright spot, while cash generation and institutional/insider signals are weak. Valuation tradeoffs are difficult to assess because earnings-based multiples are not available in source data. Upside drivers would need to come from catalysts rather than current fundamentals, and the rating itself flags distribution risk.

Recent Catalysts & News Wire Analysis

  • Late-stage testing (MARKET WIRE, YELLOW): Per the news feed, a spinal cord injury drug is described as entering late-stage testing to assess hand function and quality of life.
  • Pivotal Phase 3 start (MARKET WIRE, YELLOW): Per Streetwise Reports, NervGen has begun a pivotal Phase 3 test of NVG-291 in chronic spinal cord injury.
  • Price action notes (MARKET WIRE, YELLOW): Multiple items report price moves toward resistance, including a 4.23% rise to $1.48 and a 5.99% climb to $1.50.
  • Beta Neutral Pair (CATALYST, GREEN): One item describes shares pressing against resistance at $1.43.
  • Risk Watch (RED): Per the news feed, shares dropped -5.33% in a session flagged as a covered call trade setup.

The Butterfly supply-chain graph lists no supply chain links and no proprietary signals, so no cross-company signal read-through is available.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The only sector context provided is Health Care / Biotechnology: Pharmaceutical Preparations, which is not sufficient to map ripple effects.

Open Questions

  • What are the specific financial results (revenue, operating income, net income, cash, and debt) across reported periods?
  • What are the P/E, forward P/E, EV/EBITDA, and EPS figures that would allow valuation comparison?
  • What is the Phase 3 timeline and what endpoints define success for NVG-291?
  • Who are the institutional holders and what recent 13F, Form 4, or Congressional trades exist?
  • What analyst consensus ratings and price targets exist for NGEN?

NGEN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NervGen Pharma Corp. (NGEN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NGEN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NGEN Bull vs. Bear Conversation Board — What's Your Call at $1.37?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NGEN 🐻 50% BEARISH CONVICTION
1. Pick Your Side on NGEN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $1.56 (+8.3%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is NGEN (D • RQD 49/100) a Buy at $1.44?

Welcome to the NGEN (NervGen Pharma Corp.) Roar Pit. Current RQD Composite is 49/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.18 (-18.1%)
Spot @ $1.44

Pump the brakes on NGEN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NGEN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless NervGen Pharma Corp. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.67 (+16.0%)
Spot @ $1.44

NGEN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NGEN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.44 (52-wk range $1.34 - $1.66), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%